Big story in the WSJ, but I’m not surprised in the least. Three points: 1. Amazingly, the FDA has no public surveillance system for counterfeit
Did the media report the Avastin label revocation correctly? Predictably, the WSJ Opinion page missed the science boat, but the journalists – NYTimes, Reuters, ABC
Today the FDA Commissioner recommends revoking the Avastin label for metastatic breast cancer. As we’ve said before, the FDA is not: Pulling Avastin from the
The controversial FDA Avastin hearings were yesterday and today. (Prior TIE coverage here) My expectations for evidence-based reporting were low. But with the exception of
One of my daughters once asked me about Avastin while we were standing in line (we’re a wonky family). I talked about progression-free survival for
Avastin is the canary in the health technology assessment (HTA) coal mine. If we can’t get HTA right on Avastin, then science-based reimbursement may be
Sound Medicine is a radio show produced by the Indiana University School of Medicine and WFYI Public Radio. In the last few years, I’ve become
The following originally appeared on The Upshot (copyright 2015, The New York Times Company). Competition among generic drug makers pushes drug prices downward. But such competition is
I recommend Lisa Rosenbaum’s three-part NEJM series on financial conflicts of interest (links: part 1, part 2, and part 3). Though it is thought provoking throughout, this single sentence
Below are my notes from reading David Cutler’s The Quality Cure. Indented bits are paraphrases. Block quotes are direct quotes, obviously. Unintended bits are my commentary.
Great editorial today in BloombergView on Medicare’s payment practices for drug administration: Here’s how the system works: When a doctor administers a drug in his
the health services research blog
Work posted here under copyright © of the authors • Details on the Site Policies page
